Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887467 | 1.00 | CTSK (0.50) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL14314073 | 0.95 | CTSK (0.49) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL25526249 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL9542339 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL25526261 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL28854991 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL30601914 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL25526146 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL30219212 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS | |
| SCHEMBL26277055 | 0.94 | CTSK (0.48) | CTSKCA1CA2CA7CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115175735-A | Antiviral compounds | 吉利德科学公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-115135383-A | Antiviral compounds | 吉利德科学公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115087659-A | Antiviral compounds | 吉利德科学公司 | 2022-09-20 | — | — | CN | disclosed |
| EP-2928504-B1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS INC (US) | 2019-02-20 | — | — | EP | disclosed |
| EP-2173724-B1 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8232285-B2 | Quinazolinone compounds and methods of use thereof | ARQULE, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2173724-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | ARQULE, INC. (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2009002808-A2 | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217300-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | CTSK 553/4885CA1 2490/4885CA2 1688/4885 |
| US-20090130097-A1 | Quinazolinone Compounds and Methods of Use Thereof | NQO2, NQO1, MKI67 | CTSK 553/4885CA1 2490/4885CA2 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.